Department of Internal Medicine, Federal University of Rio de Janeiro, 255 Professor Rodolpho Paulo Rocco Av, Rio de Janeiro, 21941-913, Brazil.
Department of Internal Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Hepatol Int. 2024 Oct;18(5):1396-1415. doi: 10.1007/s12072-024-10716-z. Epub 2024 Aug 8.
Non-alcoholic fatty liver disease (NAFLD) is present in lean people. However, the magnitude of the prognostic hepatic and cardiovascular risk in these patients compared to non-lean counterparts remains unclear. We aimed to investigate this topic, and to explore whether these risks change based on factors related to NAFLD severity.
PubMed and Embase databases were searched for cohort studies (published through April 2024) that evaluated liver and cardiovascular (CV) outcomes in lean and non-lean individuals with NAFLD and reported unadjusted or adjusted data. We pooled risk ratios (RRs) or hazard ratios (HRs) using a random-effects modeling and performed subgroup and meta-regressions analyses.
We identified 22 studies with over 1 million NAFLD patients (13.0% were lean). Lean NAFLD showed a similar risk of liver-related events in unadjusted analysis (RR 1.08, 95% CI 0.79-1.49, I = 31%), but a higher risk in adjusted analysis (HR 1.66, 95% CI 1.17-2.36, I = 83%) compared to non-lean NAFLD. Lean NAFLD had a higher risk of liver-related mortality (RR 2.22, 95% CI 1.57-3.15, I = 0%; HR 2.26, 95% CI 1.14-4.51, I = 0%). For CV outcomes, lean NAFLD had a lower risk of any cardiovascular disease in unadjusted analysis (RR = 0.82, 95% CI 0.70-0.95, I = 88%), but similar risk in adjusted analysis (HR 0.89, 95% CI 0.77-1.02, I = 78%), and similar risk of cardiovascular mortality (RR 1.09, 95% CI 0.71-1.66, I = 85%; HR 1.26, 95% CI 0.89-1.78, I = 46%) compared to non-lean NAFLD.
Lean NAFLD patients have worse liver outcomes, but similar CV outcomes compared to non-lean NAFLD patients, highlighting the importance of monitoring both groups closely.
非酒精性脂肪性肝病(NAFLD)可发生于瘦人群体中。然而,与非瘦人群体相比,这些患者的肝脏和心血管预后的严重程度尚不清楚。本研究旨在探讨这一问题,并探讨这些风险是否会因与 NAFLD 严重程度相关的因素而改变。
检索了截至 2024 年 4 月发表的评估非酒精性脂肪性肝病瘦患者和非瘦患者的肝脏和心血管结局的队列研究,评估了未经调整或调整后的数据。我们使用随机效应模型汇总风险比(RR)或风险比(HR),并进行亚组和荟萃回归分析。
共纳入 22 项研究,涉及超过 100 万例 NAFLD 患者(13.0%为瘦患者)。未经调整分析中,瘦患者的肝脏相关事件风险相似(RR 1.08,95%CI 0.79-1.49,I=31%),但调整后分析中风险更高(HR 1.66,95%CI 1.17-2.36,I=83%)。与非瘦患者相比,瘦患者的肝脏相关死亡率更高(RR 2.22,95%CI 1.57-3.15,I=0%;HR 2.26,95%CI 1.14-4.51,I=0%)。对于心血管结局,未经调整分析中,瘦患者的任何心血管疾病风险较低(RR=0.82,95%CI 0.70-0.95,I=88%),但调整后分析中风险相似(HR=0.89,95%CI 0.77-1.02,I=78%),且心血管死亡率风险相似(RR=1.09,95%CI 0.71-1.66,I=85%;HR=1.26,95%CI 0.89-1.78,I=46%)。
与非瘦患者相比,瘦患者的肝脏结局更差,但心血管结局相似,这突出了密切监测两组患者的重要性。